KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP grew its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 40.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,923 shares of the specialty pharmaceutical company’s stock after acquiring an additional 33,900 shares during the period. Wellington Management Group LLP owned about 0.27% of KalVista Pharmaceuticals worth $1,366,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in KALV. nVerses Capital LLC bought a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. increased its position in KalVista Pharmaceuticals by 67.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after buying an additional 3,328 shares during the period. Intech Investment Management LLC bought a new stake in KalVista Pharmaceuticals in the third quarter valued at $126,000. SG Americas Securities LLC acquired a new position in shares of KalVista Pharmaceuticals during the third quarter valued at $153,000. Finally, Quest Partners LLC bought a new position in shares of KalVista Pharmaceuticals during the third quarter worth about $175,000.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,627 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $9.75, for a total value of $74,363.25. Following the completion of the sale, the chief executive officer now directly owns 274,596 shares of the company’s stock, valued at approximately $2,677,311. This represents a 2.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the transaction, the insider now directly owns 94,199 shares in the company, valued at $872,282.74. This represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,291 shares of company stock worth $304,086 over the last ninety days. Company insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock opened at $8.09 on Friday. KalVista Pharmaceuticals, Inc. has a 12-month low of $8.07 and a 12-month high of $16.88. The stock has a market capitalization of $399.79 million, a PE ratio of -2.22 and a beta of 0.85. The firm has a 50 day simple moving average of $10.44 and a 200-day simple moving average of $11.66.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Bank of America started coverage on KalVista Pharmaceuticals in a research report on Wednesday. They issued a “buy” rating and a $22.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).